应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NVO 诺和诺德
休市中 02-06 16:00:00 EST
47.64
+4.30
+9.92%
盘后
49.94
+2.30
+4.83%
19:59 EST
最高
47.74
最低
45.84
成交量
3,686万
今开
46.37
昨收
43.34
日振幅
4.38%
总市值
2,115亿
流通市值
1,519亿
总股本
44.39亿
成交额
17.23亿
换手率
1.16%
流通股本
31.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局
多肽圈 · 02-07 09:00
行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局
欧洲股市在震荡中走强 诺和诺德反弹抵消了Stellantis的重挫
环球市场播报 · 02-07 01:48
欧洲股市在震荡中走强 诺和诺德反弹抵消了Stellantis的重挫
诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现
新浪财经 · 02-07 01:14
诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现
异动解读 | FDA警告打击非法仿制药，诺和诺德盘中大涨8.21%
异动解读 · 02-07 00:43
异动解读 | FDA警告打击非法仿制药，诺和诺德盘中大涨8.21%
Hims & Hers跌近10%、诺和诺德涨超7%、礼来涨超3%！美国FDA警告将对“非法仿冒药物”采取行动
老虎资讯综合 · 02-06 22:44
Hims & Hers跌近10%、诺和诺德涨超7%、礼来涨超3%！美国FDA警告将对“非法仿冒药物”采取行动
FDA承诺重拳出击仿制减肥药灰产，诺和诺德、礼来股价反弹
智通财经 · 02-06 18:45
FDA承诺重拳出击仿制减肥药灰产，诺和诺德、礼来股价反弹
解码“新药王”：替尔泊肽的制胜逻辑与减肥药市场三大变局
药创新 · 02-06 18:05
解码“新药王”：替尔泊肽的制胜逻辑与减肥药市场三大变局
异动解读 | FDA警告打击非法仿制药，诺和诺德盘前大涨6.39%
异动解读 · 02-06 17:05
异动解读 | FDA警告打击非法仿制药，诺和诺德盘前大涨6.39%
诺和诺德在法兰克福上市的股票上涨2.5%。此前，美国食品药品监督管理局（FDA）警告将对“非法仿冒药物”采取行动。
格隆汇 · 02-06 15:29
诺和诺德在法兰克福上市的股票上涨2.5%。此前，美国食品药品监督管理局（FDA）警告将对“非法仿冒药物”采取行动。
诺和诺德：非法Wegovy风险巨大，将对Hims & Hers采取法律行动
格隆汇 · 02-06 10:04
诺和诺德：非法Wegovy风险巨大，将对Hims & Hers采取法律行动
全球“药王”易主，替尔泊肽“上位”
药渡 · 02-06 07:32
全球“药王”易主，替尔泊肽“上位”
诺和诺德暴跌8%，新减肥药片刚上市就遭"山寨"，远程医疗公司Hims推出49美元仿制药
华尔街见闻 · 02-06 07:09
诺和诺德暴跌8%，新减肥药片刚上市就遭"山寨"，远程医疗公司Hims推出49美元仿制药
诺和诺德威胁对Hims&Hers的“复方配制”减肥药采取法律行动
环球市场播报 · 02-06 05:01
诺和诺德威胁对Hims&Hers的“复方配制”减肥药采取法律行动
异动解读 | 仿制药冲击叠加竞争担忧，诺和诺德盘中大跌8.17%
异动解读 · 02-06 04:19
异动解读 | 仿制药冲击叠加竞争担忧，诺和诺德盘中大跌8.17%
诺和诺德2025财年实现净利润154.90亿美元，同比增加5.76%
市场透视 · 02-06 00:00
诺和诺德2025财年实现净利润154.90亿美元，同比增加5.76%
诺和诺德就Him & Hers仿冒司美格鲁肽一事发布声明：将对Him & Hers采取法律行动
新浪财经 · 02-05 23:53
诺和诺德就Him & Hers仿冒司美格鲁肽一事发布声明：将对Him & Hers采取法律行动
诺和诺德盘中异动 早盘股价大跌4.02%报45.29美元
市场透视 · 02-05 22:42
诺和诺德盘中异动 早盘股价大跌4.02%报45.29美元
Hims & Hers Health推出Wegovy减肥药的仿制品，售价为49美元
老虎资讯综合 · 02-05 22:36
Hims & Hers Health推出Wegovy减肥药的仿制品，售价为49美元
诺和诺德CEO称服用Hims复方药片者将"浪费49美元"，因化合物无法被吸收——分析师电话会议实录
美股速递 · 02-05 22:32
诺和诺德CEO称服用Hims复方药片者将"浪费49美元"，因化合物无法被吸收——分析师电话会议实录
美股异动丨Hims&Hers Health推出Wegovy复方制剂，诺和诺德、礼来盘前跳水
格隆汇 · 02-05 22:00
美股异动丨Hims&Hers Health推出Wegovy复方制剂，诺和诺德、礼来盘前跳水
加载更多
公司概况
公司名称：
诺和诺德
所属市场：
NYSE
上市日期：
--
主营业务：
Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。
发行价格：
--
{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":47.64,"timestamp":1770411600000,"preClose":43.34,"halted":0,"volume":36856625,"hourTrading":{"tag":"盘后","latestPrice":49.94,"preClose":47.64,"latestTime":"19:59 EST","volume":1425367,"amount":70042190.0627,"timestamp":1770425994019,"change":2.3,"changeRate":0.048279,"amplitude":0.065611},"delay":0,"changeRate":0.0992155053068758,"floatShares":3187922885,"shares":4439052849,"eps":3.620568,"marketStatus":"休市中","change":4.3,"latestTime":"02-06 16:00:00 EST","open":46.37,"high":47.74,"low":45.84,"amount":1722835293.15625,"amplitude":0.043839,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.620568,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":43.34,"dividendRate":0.035429,"preHourTrading":{"tag":"盘前","latestPrice":46.36,"preClose":43.34,"latestTime":"09:29 EST","volume":1602735,"amount":74271852.19809,"timestamp":1770388199999,"change":3.02,"changeRate":0.069682,"amplitude":0.022381},"postHourTrading":{"tag":"盘后","latestPrice":49.94,"preClose":47.64,"latestTime":"19:59 EST","volume":1425367,"amount":70042190.0627,"timestamp":1770425994019,"change":2.3,"changeRate":0.048279,"amplitude":0.065611},"volumeRatio":0.9215358699407029,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1771563600000,"strike":"51.0","timestamp":1770390472794,"price":0.61,"volume":24093,"amount":1469673,"type":"-"},{"symbol":"NVO","call":false,"expireDate":1772168400000,"strike":"47.0","timestamp":1770407286864,"price":2.06,"volume":14100,"amount":2904600,"type":"-"}]},"impliedVol":0.5293,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2609543571","title":"行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609543571","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609543571?lang=zh_cn&edition=full","pubTime":"2026-02-07 09:00","pubTimestamp":1770426012,"startTime":"0","endTime":"0","summary":"过去一年里，所谓的 “Tide” 军团中仅有四款新药获得 FDA 批准，而其中的主角并非多肽，而是寡核苷酸。该药于 2025 年 9 月获得 FDA 加速批准，用于改善 Barth 综合征患者的肌力，也由此成为这一病种的首个获批治疗选择。2025 年更像是一个多肽药物的“调整期”，而非真正的高光时刻。从 FDA 已披露的新药审评进度来看，一批多肽类 NCE 以及以多肽为关键驱动的产品形态，已经接近关键节点。FDA已受理其NDA并给出2026年8月28日的PDUFA目标日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","BK4023","BK4588","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4599","NVOX","NVO"],"gpt_icon":1},{"id":"2609139075","title":"欧洲股市在震荡中走强 诺和诺德反弹抵消了Stellantis的重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2609139075","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609139075?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:48","pubTimestamp":1770400080,"startTime":"0","endTime":"0","summary":"欧洲股市周五在震荡中走强，制药商诺和诺德反弹，帮助抵消了汽车股的疲软。诺和诺德上涨5.3%，过去一周由于市场担心其减重药Wegovy出现“仿制版”，公司市值缩水近四分之一。汽车股跌幅居前，Stellantis NV在宣布计提约220亿欧元与全面重组相关的费用后暴跌25%；在成本高企、电动车销量低迷的背景下，该公司准备进行大规模改革。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-07/doc-inhkxipt7729392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","NVOX","LU0154236417.USD","BK4007","STLA","IE00BZ1G4Q59.USD","BK4099","BK4532","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","BK4534","NVO","LU1064927863.SGD","LU1093756168.USD","BK4588","NVOH"],"gpt_icon":1},{"id":"2609513560","title":"诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2609513560","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609513560?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:14","pubTimestamp":1770398053,"startTime":"0","endTime":"0","summary":"尽管周五股价小幅反弹，该股仍难逃六个月来的最差单周表现。自 2024 年 6 月市值触及 6590 亿美元峰值后，诺和诺德多年来的惊人涨幅化为乌有。诺和诺德将欧唐静的有效成分司美格鲁肽重新研发，打造出专用于减肥的维格卫，并于 2021 年 6 月获得美国监管机构批准上市，推动公司股价一路飙升。原本，维格卫口服版的上市被视为诺和诺德巩固竞争优势的契机，公司股价 1 月的反弹也创下五个月来最大涨幅。诺和诺德发布声明时，其股价盘中跌幅已达 10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4585","LU1093756325.SGD","BK4599","NVOX","LU0154236417.USD","NVO","BK4007"],"gpt_icon":1},{"id":"1164090134","title":"异动解读 | FDA警告打击非法仿制药，诺和诺德盘中大涨8.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164090134","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164090134?lang=zh_cn&edition=full","pubTime":"2026-02-07 00:43","pubTimestamp":1770396204,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘中大幅上涨8.21%，引起了市场的广泛关注。这一监管信号被视为对诺和诺德旗下重磅减肥药Wegovy等品牌药物的保护，有效缓解了市场对低价仿制版本冲击的担忧，从而提振了投资者信心。此外，高盛发布研报认为，市场对诺和诺德面临的定价压力反应过度，目前的股价实际上已经完全计入了公司2026财年指引的下限。同时，诺和诺德董事会决定启动一项高达150亿丹麦克朗的新股票回购计划，也增强了投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"1197070285","title":"Hims & Hers跌近10%、诺和诺德涨超7%、礼来涨超3%！美国FDA警告将对“非法仿冒药物”采取行动","url":"https://stock-news.laohu8.com/highlight/detail?id=1197070285","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197070285?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:44","pubTimestamp":1770389098,"startTime":"0","endTime":"0","summary":"2月6日，Hims & Hers Health跌近10%、$诺和诺德(NVO)$涨超7%、$礼来(LLY)$涨超3%！美国FDA警告将对“非法仿冒药物”采取行动。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54b8f1b5bb351d5dbee0b764be70e208","theme_name":"热榜No.10 · 诺和诺德美股盘前大幅反弹，股价涨超6%，FDA打击非法仿制药品","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU2168564222.USD","LU0889565916.HKD","LU0323591593.USD","LU1323610961.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0354030438.USD","BK4585","LU2089984988.USD","LU2361045086.USD","LU0823434740.USD","LU2360106947.USD","LU0823416689.USD","LU1069344957.HKD","LU2552382132.HKD","IE00BJJMRX11.SGD","LU1023059063.AUD","LU1814569148.SGD","LU0114720955.EUR","LU2357305700.SGD","LU0417517546.SGD","BK4534","LU2471134952.CNY","LU2023250504.SGD","LU1974910355.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU1868836757.USD","LU2089283258.USD","LU0266013472.USD","LU0289739699.SGD","LU0234572021.USD","LU0316494557.USD","LU0471298694.HKD","LU1366192091.USD","SG9999001176.SGD","LU2756315318.SGD","IE00BKPKM429.USD","LU1057294990.SGD","LU0471298777.SGD","LU1127390331.HKD","LU1623119135.USD","LU0964807845.USD","GB00BDT5M118.USD","LU1267930730.SGD","LU0094547139.USD","BK4599","LU2023251221.USD","IE0005OL40V9.USD","LU0256863902.USD","LU1551013342.USD","LU1868837300.USD","LU0672654240.SGD","IE00BFSS8Q28.SGD","LU2265009873.SGD","LU2324357040.USD","SG9999017495.SGD","LU2168564149.EUR","LU2361044865.SGD","SGXZ57979304.SGD","LU2237443549.SGD","LU0225283273.USD","LU0106261372.USD","LU0109394709.USD","LU2756315664.SGD","LU2491049909.HKD","IE00BJLML261.HKD","LU1868837136.USD","SG9999015978.USD","LU1551013425.SGD","LU0320765992.SGD","LU0787776722.HKD","LU0640476718.USD","LU1720051017.SGD","SG9999015945.SGD","LU0320765059.SGD","LU2087625088.SGD","LU2213496289.HKD","SGXZ31699556.SGD","LU0820561909.HKD","SG9999014880.SGD","LU2491050071.SGD","LU0786609619.USD","LU1629891620.HKD","LU1712237335.SGD","IE00B1XK9C88.USD","LU2750360641.GBP","LU2750360997.AUD","IE00BKVL7J92.USD","LU0238689110.USD","LU2237443895.HKD","LU2552382215.SGD","SG9999018865.SGD","BK4516","BK4581","IE00BKDWB100.SGD","LU0058720904.USD","LU1280957306.USD","LU2462157665.USD","LU2602419157.SGD","SG9999015952.SGD","IE00B1BXHZ80.USD","IE0004445239.USD","LU0203202063.USD","LU2112291526.USD","LU0006306889.USD","LU0432979614.USD","LU2896262040.SGD","SG9999018857.SGD","LU2468319806.SGD","IE00BN29S564.USD","LU2271345857.HKD","LU2168563687.JPY","SGXZ51526630.SGD","LU1989771016.USD","IE0009355771.USD","IE00B4JS1V06.HKD","LU2111349929.HKD","LU1804176565.USD","LU2471134796.USD","LU0079474960.USD","LU0820562030.AUD","LU2417539215.USD","LU1548497426.USD","LU2746668974.SGD","LU2264538146.SGD","LU1145028129.USD","IE00BZ1G4Q59.USD","LU0256863811.USD","LU2023250330.USD","BK4532","IE00BJJMRZ35.SGD","SG9999014898.SGD","SGXZ81514606.USD","LU2211815571.USD","LU1061106388.HKD","LU2361044949.HKD","LU2237443622.USD","LU0820561818.USD","LU0353189763.USD","LU2028103732.USD","SG9999014906.USD","LU0061475181.USD","LU2106854487.HKD","LU1917777945.USD","LU1035775433.USD","LU1291159041.SGD","IE00BJT1NW94.SGD","IE00BK4W5M84.HKD","LU0354030511.USD","LU2746668461.USD","LU0943347566.SGD","LU1988902786.USD","LU0154236417.USD","LU2168564495.EUR","LU2491050154.USD","LU2552382058.USD","LU0823434583.USD","LU0882574139.USD","LU2456880835.USD","LU2237438978.USD","BK4588","LU2461242641.AUD","LU1983299246.USD","IE00B775H168.HKD","IE00BFSS7M15.SGD","IE00BWXC8680.SGD","LU2471134523.USD","IE0002141913.USD","LU0689472784.USD","LU0109391861.USD","LU2237443978.SGD","LU1093756325.SGD","LU2108987350.USD","LU0385154629.USD","LU0456855351.SGD","LU2168564065.EUR","LU0683600562.USD","LU2089284900.SGD","LU2063271972.USD","LU0882574055.USD","LU0353189680.USD","LU1232071149.USD","LU1868836591.USD","LU1093756168.USD","IE0004445015.USD","IE00B7KXQ091.USD","SG9999014914.USD","LU0158827948.USD","LU0203201768.USD","LU0708995401.HKD","BK4533","LU0198837287.USD","LU1064131342.USD","LU1868836914.USD","NVO","SG9999001176.USD","BK4007","LU0158827781.USD","LU2236285917.USD","SG9999013999.USD","HIMS","LU0097036916.USD","LU2237443382.USD","LU2237443465.HKD","LU2471134879.HKD","LU0466842654.USD","IE00BJJMRY28.SGD","LLY","LU0210536198.USD","SGXZ99366536.SGD","IE00BK4W5L77.USD","SG9999015986.USD","LU0096364046.USD"],"gpt_icon":0},{"id":"2609564968","title":"FDA承诺重拳出击仿制减肥药灰产，诺和诺德、礼来股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2609564968","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609564968?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:45","pubTimestamp":1770374707,"startTime":"0","endTime":"0","summary":"在美股盘前交易中，诺和诺德美股ADR交易价格一度大涨超8%；礼来也在昨日跌近8%后，涨近4%。在周四，美国远程医疗公司Hims and Hers Health推出了诺和诺德获FDA批准的减重药Wegovy片剂版本的显著更便宜的49美元复方仿制版本，这引发了减肥药双雄诺和诺德和礼来股价的下跌。在FDA局长发布上述推文之后，Hims & Hers Health股价在美股盘前暴跌，跌幅一度超过7%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0fce81d99e7c4115b5691df849cabad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402635.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA承诺重拳出击仿制减肥药灰产，诺和诺德、礼来股价反弹","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","LU0203202063.USD","LU1868837136.USD","LU1280957306.USD","LU2112291526.USD","LU0256863902.USD","LU0786609619.USD","LU2237438978.USD","LU2491050154.USD","BK4599","IE00B1BXHZ80.USD","LU1868836591.USD","LU0094547139.USD","LU1551013425.SGD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU0683600562.USD","LU2063271972.USD","IE0004445239.USD","SGXZ51526630.SGD","LU2462157665.USD","BK4007","LU0203201768.USD","IE00B7KXQ091.USD","IE00BKDWB100.SGD","LU0198837287.USD","LU2023251221.USD","LU0158827948.USD","LU2361044949.HKD","LU2108987350.USD","SG9999014898.SGD","BK4534","LU1804176565.USD","LU1629891620.HKD","LU0096364046.USD","LU2552382215.SGD","LU1868836757.USD","LU1983299246.USD","LU2237443382.USD","LU0225283273.USD","SG9999001176.USD","LU2213496289.HKD","LU2324357040.USD","LU1868836914.USD","LU0964807845.USD","LU0154236417.USD","IE0002141913.USD","SG9999018857.SGD","LU2237443895.HKD","LU1323610961.USD","IE00B2B36J28.USD","LU0417517546.SGD","LU2552382058.USD","SG9999014914.USD","LU1989771016.USD","LU2750360997.AUD","SGXZ99366536.SGD","LU0114720955.EUR","LU0320765059.SGD","LU0889565916.HKD","LU1023059063.AUD","LU2491050071.SGD","LU0820561909.HKD","IE00BJJMRZ35.SGD","SG9999015986.USD","LLY","SGXZ57979304.SGD","BK4588","LU1093756168.USD","LU1974910355.USD","LU2360106947.USD","LU1917777945.USD","GB00BDT5M118.USD","SG9999017495.SGD","LU1064131342.USD","IE00BJLML261.HKD","LU0006306889.USD","LU0097036916.USD","LU0266013472.USD","LU2471134523.USD","LU2602419157.SGD","LU1061106388.HKD","LU0353189680.USD","IE00BFSS7M15.SGD","LU1267930730.SGD","LU0708995401.HKD","HIMS","LU0353189763.USD","NVO","LU0289739699.SGD","LU0820561818.USD","LU1366192091.USD","SG9999018865.SGD","LU2168563687.JPY","LU1232071149.USD","LU0471298777.SGD","LU0466842654.USD","LU1720051108.HKD","BK4516","LU2264538146.SGD","LU1868837300.USD","LU0672654240.SGD","LU2471134952.CNY","LU0316494557.USD","LU2456880835.USD","LU2756315664.SGD","LU1291159041.SGD","SG9999015952.SGD","LU0256863811.USD","LU2471134796.USD","LU2265009873.SGD","LU0109391861.USD","LU1035775433.USD","LU2237443549.SGD","LU2417539215.USD","LU1988902786.USD","IE00BJJMRY28.SGD","LU0354030438.USD","LU2750360641.GBP","IE00BN29S564.USD","LU0158827781.USD","LU2237443978.SGD","SG9999001176.SGD","LU2746668461.USD","SGXZ31699556.SGD","SG9999015978.USD","LU0432979614.USD","LU0061475181.USD","LU0689472784.USD","LU0823434583.USD","IE00BK4W5L77.USD","IE00B4R5TH58.HKD","LU2106854487.HKD","LU2023250504.SGD","LU2168564149.EUR","LU0471298694.HKD","LU0823434740.USD","LU0210536198.USD","LU0079474960.USD","SGXZ81514606.USD","BK4533","LU2357305700.SGD","LU0943347566.SGD","LU2552382132.HKD","SG9999014906.USD","SG9999015945.SGD","LU0058720904.USD","LU2111349929.HKD","LU2237443622.USD","LU0323591593.USD","LU2361044865.SGD","LU0882574055.USD","BK4585","LU1069344957.HKD","LU0109394709.USD","LU2089283258.USD","IE00BKPKM429.USD","IE00BKVL7J92.USD","LU0122379950.USD","LU2089984988.USD","LU2271345857.HKD","IE00BWXC8680.SGD","LU0456855351.SGD","SG9999014880.SGD","BK4532","LU1720051017.SGD","LU1623119135.USD","LU2746668974.SGD","LU2087625088.SGD","IE00B4JS1V06.HKD","LU0787776722.HKD","LU2471134879.HKD","IE00BK4W5M84.HKD","LU2028103732.USD","IE0004445015.USD","IE00BJJMRX11.SGD","LU0640476718.USD","LU1057294990.SGD","IE00B1XK9C88.USD","LU2896262040.SGD","LU2756315318.SGD","LU0354030511.USD","BK4581","LU0234572021.USD","LU0320765992.SGD","LU0385154629.USD","LU1127390331.HKD","LU1548497426.USD","LU0820562030.AUD","LU1093756325.SGD","LU0238689110.USD","LU1712237335.SGD","SG9999013999.USD","LU0882574139.USD","LU0823416689.USD","IE0009355771.USD","LU1551013342.USD","LU2168564065.EUR","LU2461242641.AUD","LU0106261372.USD","IE00BFSS8Q28.SGD","LU2491049909.HKD","LU2089284900.SGD","LU2168564222.USD","LU2237443465.HKD","LU1145028129.USD","LU2468319806.SGD","LU2211815571.USD","LU1814569148.SGD","IE00B775H168.HKD","LU2168564495.EUR","IE0005OL40V9.USD","IE00BFTCPJ56.SGD","LU2361045086.USD","LU2023250330.USD"],"gpt_icon":1},{"id":"2609560297","title":"解码“新药王”：替尔泊肽的制胜逻辑与减肥药市场三大变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609560297","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609560297?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:05","pubTimestamp":1770372327,"startTime":"0","endTime":"0","summary":"而新药王，正是礼来的替尔泊肽。尽管Keytruda退下药王宝座令人唏嘘，但替尔泊肽成为“新王”却不那么令人惊讶，它在糖尿病与减重两条重磅级赛道的突出表现，令这样的结局变得顺理成章。但替尔泊肽以更快的放量速度完成了对Keytruda的年度销售额超越。CagriSema的首个监管申请可能会在今年第一季度提交。另一家在减肥药开发市场意欲","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020619450397a5341b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020619450397a5341b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4532","BK4599","BK4585","BK4007","BK4588","LU1093756325.SGD","NVOX","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD","NVOH"],"gpt_icon":1},{"id":"1118065622","title":"异动解读 | FDA警告打击非法仿制药，诺和诺德盘前大涨6.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118065622","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118065622?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:05","pubTimestamp":1770368717,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘前股价大幅上涨6.39%，引起了市场的广泛关注。这一监管信号被视为对诺和诺德旗下重磅减肥药Wegovy等品牌药物的保护，有效缓解了市场对低价仿制版本冲击的担忧。此外，高盛发布研报认为，市场对诺和诺德面临的定价压力反应过度，目前的股价实际上已经完全计入了公司2026财年指引的下限。同时，诺和诺德董事会决定启动一项高达150亿丹麦克朗的新股票回购计划，也增强了投资者信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"54b8f1b5bb351d5dbee0b764be70e208","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"2609968557","title":"诺和诺德在法兰克福上市的股票上涨2.5%。此前，美国食品药品监督管理局（FDA）警告将对“非法仿冒药物”采取行动。","url":"https://stock-news.laohu8.com/highlight/detail?id=2609968557","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609968557?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:29","pubTimestamp":1770362993,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","NVOH","BK4599","NVOX","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4007","BK4532","BK4588"],"gpt_icon":0},{"id":"2609615534","title":"诺和诺德：非法Wegovy风险巨大，将对Hims & Hers采取法律行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609615534","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609615534?lang=zh_cn&edition=full","pubTime":"2026-02-06 10:04","pubTimestamp":1770343441,"startTime":"0","endTime":"0","summary":"给患者健康带来了巨大风险。","market":"us","thumbnail":"https://static.tigerbbs.com/bbb79ccf38ea59e0e72b97344595ad53","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bbb79ccf38ea59e0e72b97344595ad53"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0fce81d99e7c4115b5691df849cabad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","HIMS","LLY"],"gpt_icon":0},{"id":"2609253532","title":"全球“药王”易主，替尔泊肽“上位”","url":"https://stock-news.laohu8.com/highlight/detail?id=2609253532","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609253532?lang=zh_cn&edition=full","pubTime":"2026-02-06 07:32","pubTimestamp":1770334337,"startTime":"0","endTime":"0","summary":"2025年，司美格鲁肽在前两个季度成功反超帕博利珠单抗，一度坐上全球药王宝座，但最终又被替尔泊肽以约不足5亿美元的微弱优势超越。在具体减重数值上，替尔泊肽组患者平均减重22.8公斤，司美格鲁肽组则为15.0公斤。腰围缩减方面，替尔泊肽组平均减少18.4厘米，司美格鲁肽组减少13.0厘米。Nature Reviews Drug Discovery对2026年全球药品销售的预测显示，替尔泊肽的领先优势可能进一步扩大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206073725a6d8d961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206073725a6d8d961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVOH","LLY","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","NVOX","BK4532","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","BK4585","BK4588","LU0154236417.USD"],"gpt_icon":1},{"id":"2609553873","title":"诺和诺德暴跌8%，新减肥药片刚上市就遭\"山寨\"，远程医疗公司Hims推出49美元仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2609553873","media":"华尔街见闻","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609553873?lang=zh_cn&edition=full","pubTime":"2026-02-06 07:09","pubTimestamp":1770332988,"startTime":"0","endTime":"0","summary":"远程医疗公司Hims推出仿制版，定价99美元/月，远低于品牌药149美元。诺和诺德指责其\"非法复配\"并威胁起诉，声称仿制品缺乏专有保护技术无法有效吸收。Hims辩称采用不同配方。受此影响，诺和诺德股价暴跌超8%。","market":"nz","thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3765104","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3765104","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺和诺德暴跌8%，新减肥药片刚上市就遭\"山寨\"，远程医疗公司Hims推出49美元仿制药","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","NVOH","NVOX","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4599","BK4007","NVO"],"gpt_icon":1},{"id":"2609393581","title":"诺和诺德威胁对Hims&Hers的“复方配制”减肥药采取法律行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609393581","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609393581?lang=zh_cn&edition=full","pubTime":"2026-02-06 05:01","pubTimestamp":1770325289,"startTime":"0","endTime":"0","summary":"日益拥挤的肥胖治疗市场竞争不断升温，在美国远程医疗集团Hims&Hers推出丹麦制药商诺和诺德减肥药Wegovy片剂的更便宜版本后，诺和诺德已威胁采取法律行动。诺和诺德上月开始在美国销售Wegovy口服片剂，最低剂量月价为149美元，这是全球首个获得监管机构批准的口服减肥药版本。 诺和诺德对这一举动作出强烈回应，称其为“非法的大规模复方配制”，并表示这对患者安全构成“重大风险”，公司将采取法律和监管行动以保护患者和自身专利权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0fce81d99e7c4115b5691df849cabad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-06/doc-inhkvkwq1587088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["HIMS","LU1093756168.USD","BK4599","LU0154236417.USD","LU1093756325.SGD","NVOH","NVOX","IE00BZ1G4Q59.USD","BK4585","IE00BKVL7J92.USD","BK4588","BK4532","NVO","BK4007"],"gpt_icon":1},{"id":"1179394050","title":"异动解读 | 仿制药冲击叠加竞争担忧，诺和诺德盘中大跌8.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179394050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179394050?lang=zh_cn&edition=full","pubTime":"2026-02-06 04:19","pubTimestamp":1770322750,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘中大幅下挫8.17%，引发了市场广泛关注。此举立即引发市场对减肥药市场竞争加剧以及诺和诺德定价权与市场份额可能受到侵蚀的强烈担忧，导致投资者抛售股票。此外，诺和诺德自身近期发布的业绩指引也加剧了市场的悲观情绪。面对Hims & Hers的举措，诺和诺德已表示将采取法律行动，称其行为属非法大规模配制药品，对患者安全构成风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1153e9c0a8e9571f0041cca121599eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"2609636307","title":"诺和诺德2025财年实现净利润154.90亿美元，同比增加5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609636307","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609636307?lang=zh_cn&edition=full","pubTime":"2026-02-06 00:00","pubTimestamp":1770307239,"startTime":"0","endTime":"0","summary":"2月6日，诺和诺德公布财报，公告显示公司2025财年净利润为154.90亿美元，同比增加5.76%；其中营业收入为467.36亿美元，同比增加10.97%，每股基本收益为3.49美元。从资产负债表来看，诺和诺德总负债548.55亿美元，其中短期债务18.90亿美元，资产负债比为1.56，流动比率为0.80。机构评级：截至2026年2月6日，当前有26家机构对诺和诺德目标价做出预测，其中目标均价为59.29美元，其中最低目标价为36.31美元，最高目标价为84.09美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206000049a6d7dc89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206000049a6d7dc89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4588","NVOX","LU1093756325.SGD","BK4007","BK4532","BK4599","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","NVO","IE00BZ1G4Q59.USD","NVOH"],"gpt_icon":1},{"id":"2609507307","title":"诺和诺德就Him & Hers仿冒司美格鲁肽一事发布声明：将对Him & Hers采取法律行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609507307","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609507307?lang=zh_cn&edition=full","pubTime":"2026-02-05 23:53","pubTimestamp":1770306791,"startTime":"0","endTime":"0","summary":"诺和诺德（Novo Nordisk）就Him & Hers仿冒司美格鲁肽（semaglutide）一事发布声明：将对Him & Hers采取法律行动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206000807a6d7e160&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206000807a6d7e160&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVOX","LU1093756168.USD","NVOH","BK4585","NVO","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","IE00BKVL7J92.USD","BK4588"],"gpt_icon":0},{"id":"2609012093","title":"诺和诺德盘中异动 早盘股价大跌4.02%报45.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609012093","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609012093?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:42","pubTimestamp":1770302566,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日22时42分，诺和诺德股票出现波动，股价大幅下挫4.02%。截至发稿，该股报45.29美元/股，成交量956.942万股，换手率0.22%，振幅1.46%。诺和诺德股票所在的制药行业中，整体跌幅为2.26%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522424697a50dd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"c1153e9c0a8e9571f0041cca121599eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522424697a50dd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4588","BK4532","BK4007","BK4585","IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","NVOX","NVOH","LU0154236417.USD","BK4599"],"gpt_icon":1},{"id":"1161994119","title":"Hims & Hers Health推出Wegovy减肥药的仿制品，售价为49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161994119","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161994119?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:36","pubTimestamp":1770302190,"startTime":"0","endTime":"0","summary":"2月5日，Hims & Hers Health盘前飙升10%、诺和诺德盘前大跌逾5%！消息面上，Hims & Hers Health推出了一款Wegovy减肥药的仿制品，售价为49美元。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f0fce81d99e7c4115b5691df849cabad","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hims & Hers Health推出Wegovy减肥药的仿制品，售价为49美元","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO","HIMS"],"gpt_icon":0},{"id":"1131241240","title":"诺和诺德CEO称服用Hims复方药片者将\"浪费49美元\"，因化合物无法被吸收——分析师电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1131241240","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131241240?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:32","pubTimestamp":1770301972,"startTime":"0","endTime":"0","summary":"在近日与分析师举行的电话会议中，诺和诺德首席执行官直言不讳地指出，消费者若选择服用Hims公司推出的复方药片，相当于\"平白浪费49美元\"。他解释道，这种复方制剂中的有效成分难以被人体充分吸收，导致药效大打折扣。\n这位掌舵人进一步强调，药品的生物利用度是决定疗效的关键因素。而Hims的复方药片在吸收机制上存在明显缺陷，即便成分相似，也无法达到预期治疗效果。此番表态凸显出诺和诺德对其主打产品吸收效率的自信，同时也对竞争对手产品的有效性提出质疑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1153e9c0a8e9571f0041cca121599eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4196"],"gpt_icon":0},{"id":"2609306876","title":"美股异动丨Hims&Hers Health推出Wegovy复方制剂，诺和诺德、礼来盘前跳水","url":"https://stock-news.laohu8.com/highlight/detail?id=2609306876","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609306876?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:00","pubTimestamp":1770300046,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1153e9c0a8e9571f0041cca121599eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0471298694.HKD","LU2237443895.HKD","IE00BZ1G4Q59.USD","LU0353189680.USD","LU2168564149.EUR","LU0266013472.USD","LU2471134796.USD","BK4550","LU0106261372.USD","LU2471134879.HKD","SG9999017495.SGD","SG9999015952.SGD","LU1061106388.HKD","SG9999014906.USD","LU0787776722.HKD","IE0004445239.USD","IE00BKVL7J92.USD","SGXZ31699556.SGD","LU0354030438.USD","LU1291159041.SGD","LU1323610961.USD","LU0203202063.USD","LU0094547139.USD","LU2271345857.HKD","LU0061475181.USD","LU0154236417.USD","LU1064131342.USD","UWM","LU0289739699.SGD","IE00BK4W5M84.HKD","LU0471298777.SGD","LU0456855351.SGD","LU1868836757.USD","SRTY","LU0158827948.USD","LU2491050154.USD","SG9999014880.SGD","LU0786609619.USD","LU0889565916.HKD","BK4533","IWO","LU2168563687.JPY","LU0323591593.USD","LU2028103732.USD","LU2089984988.USD","LU2468319806.SGD","LU0640476718.USD","LU1035775433.USD","IE00BJJMRY28.SGD","IE0009355771.USD","LU0823434740.USD","LU0820561818.USD","NVO","RWM","IE00BFSS8Q28.SGD","LU2108987350.USD","LU2324357040.USD","IE00B1XK9C88.USD","SG9999014914.USD","LU2750360997.AUD","LU2237443465.HKD","LU0823416689.USD","LU2112291526.USD","LU0122379950.USD","LU2023251221.USD","LU2361044949.HKD","IE00BKDWB100.SGD","BK4581","LU0823434583.USD","SG9999015978.USD","LU0943347566.SGD","LU2361045086.USD","LU0158827781.USD","LU0198837287.USD","LU1917777945.USD","BK4007","LU2023250504.SGD","TWM","LU1868836591.USD","LU2237438978.USD","SGXZ57979304.SGD","LU0672654240.SGD","IE00BKPKM429.USD","LU0353189763.USD","LU1127390331.HKD","SG9999015945.SGD","LU0109394709.USD","LU0256863902.USD","LU0210536198.USD","LU1280957306.USD","BK4516","LU0820561909.HKD","SG9999014898.SGD","LU2491050071.SGD","NVOH","LU2236285917.USD","LU2361044865.SGD","IWN","LU2237443382.USD","SGXZ51526630.SGD","SG9999013999.USD","LU2491049909.HKD","LU2265009873.SGD","LU0432979614.USD","LU1868837136.USD","LU2087625088.SGD","SG9999015986.USD","LU0316494557.USD","LU0238689110.USD","LU2168564222.USD","LU1548497426.USD","LU0256863811.USD","SG9999001176.USD","LU0109391861.USD","LU1804176565.USD","BK4585","IE00BFSS7M15.SGD","LU0689472784.USD","LU1023059063.AUD","LU0320765992.SGD","LU1868837300.USD","LU0417517546.SGD","SG9999018865.SGD","GB00BDT5M118.USD","LU0385154629.USD","LU2168564065.EUR","IE00B775H168.HKD","LU1989771016.USD","LU2746668461.USD","LU1093756168.USD","TZA","LU2746668974.SGD","LU2106854487.HKD","LU2461242641.AUD","BK4535","LU2089284900.SGD","LU2211815571.USD","LU2471134523.USD","LU2264538146.SGD","LU1232071149.USD","LU0079474960.USD","LU0708995401.HKD","LU1069344957.HKD","LU2552382132.HKD","MNQmain","LU2357305700.SGD","IE00BJLML261.HKD","LU0882574139.USD","LU2237443549.SGD","LU1988902786.USD","LU0466842654.USD","IE0004445015.USD","IE0002141913.USD","IE00B4JS1V06.HKD","IE00BN29S564.USD","LU0225283273.USD","LU0234572021.USD","IE00B1BXHZ80.USD","LU2168564495.EUR","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","NVOX","SG9999001176.SGD","IE00B4R5TH58.HKD","LU0097036916.USD","LU2237443978.SGD","LU1983299246.USD","LU2456880835.USD","SGXZ81514606.USD","IE00BK4W5L77.USD","LU1712237335.SGD","LU0882574055.USD","LU1868836914.USD","LU2750360641.GBP","LU0320765059.SGD","LU1974910355.USD","LU1551013425.SGD","BK4534","LU2552382058.USD","LU2462157665.USD","LU0058720904.USD","SG9999018857.SGD","BK4599","LU2471134952.CNY","LU0203201768.USD","IE00BJT1NW94.SGD","HIMS","IE00BFTCPJ56.SGD","LU1267930730.SGD","LU2237443622.USD","LU0354030511.USD","IE00BJJMRX11.SGD","LU0114720955.EUR","LU2089283258.USD","LU2360106947.USD","LU2417539215.USD","LU2063271972.USD","LU1623119135.USD","LU1720051017.SGD","IE00BWXC8680.SGD","LU1057294990.SGD","LU2552382215.SGD","LU0683600562.USD","SGXZ99366536.SGD","LU0006306889.USD","LU2896262040.SGD","TNA","BK4532","IE00B7KXQ091.USD","BK4588","LU1093756325.SGD","LU1366192091.USD","LU1720051108.HKD","LU1814569148.SGD","LU1551013342.USD","LU2602419157.SGD","IE0005OL40V9.USD","LU2111349929.HKD","LU0096364046.USD","LLY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.1984},{"period":"1month","weight":-0.1579},{"period":"3month","weight":0.0429},{"period":"6month","weight":-0.0673},{"period":"1year","weight":-0.4535},{"period":"ytd","weight":-0.0637}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.02303},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}